Molecular structure of Talazoparib, CAS Number: 1207456-01-6
Talazoparib (CAS 1207456-01-6)
Alternate Names:
BMN-673 BMN 673 BMN673
CAS Number:
1207456-01-6
Molecular Weight:
380.40
Molecular Formula:
C19H14F2N6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Talazoparib (CAS 1207456-01-6) References
- PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence. | Ditonno, F., et al. 2024. Clin Genitourin Cancer. 22: 402-412.e17. PMID: 38281877
- Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. | Fizazi, K., et al. 2024. Nat Med. 30: 1505. PMID: 38297094
- Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor. | Teng, QX., et al. 2024. Drug Resist Updat. 73: 101028. PMID: 38340425
- Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. | Shi, M., et al. 2024. Cancer Pathog Ther. 2: 81-90. PMID: 38601487
- Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells. | Sasaki, Y., et al. 2024. PLoS One. 19: e0302130. PMID: 38625917
- Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency. | Szallasi, Z., et al. 2024. Res Sq.. PMID: 38645014
- Poly(ADP-Ribose) Polymerases-Inhibitor Talazoparib Inhibits Muscle Atrophy and Fatty Infiltration in a Tendon Release Infraspinatus Sheep Model: A Pilot Study. | Olthof, MGL., et al. 2024. Metabolites. 14: PMID: 38668315
- New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. | Meneceur, S., et al. 2024. J Cell Mol Med. 28: e18342. PMID: 38693852
- A rare case of TFEB/6p21/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review. | Zhang, R., et al. 2024. Diagn Pathol. 19: 66. PMID: 38730456
- Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair. | Ida, N., et al. 2024. Oncol Rep. 52: PMID: 38785163
- Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US. | Pan, J., et al. 2024. Sci Rep. 14: 13935. PMID: 38886516
- Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib. | Mentzel, J., et al. 2024. Int J Mol Sci. 25: PMID: 38891817
- PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database. | Ren, X., et al. 2024. Expert Opin Drug Saf. 1-9. PMID: 38967020
Inhibitor of:
4930547N16Rik, AK7, ARH3, BABAM1, BRAP, BRCA2, BRCAA1, C12orf32, C20orf196, C9orf102, C9orf119, DNLZ, FAN, GTBP, H2-10, hMLH3, KIAA1267, MND1, MRG1, MUTYH, Olr659, Olr716, PAMR1, PAR4, Paraxis, PARP-1, PARP-10, PARP-11, PARP-12, PARP-14, PARP-15, PARP-16, PARP-2, PARP-7, PARP-8, PARP-9, Pem, PMS1, PRK2, PSG9, SA-2, TDE1, TRABID, XPV, XRCC2, and ZRANB3.Activator of:
4930547N16Rik, DNA pol θ, DNAH5, FAM111A, FANCM, FIGNL1, HPF1, Morc2b, PALB2, PARG, PARP L, PARP-4, PGBD5, and UBE2T.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Talazoparib, 10 mg | sc-507440 | 10 mg | $795.00 |